A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma

Abstract Background Transarterial chemoembolization (TACE) is the standard treatment for intermediate stage hepatocellular carcinoma (HCC) (Barcelona Clinic Liver Cancer [BCLC] B). However, it often leads to a poor prognosis and decreased hepatic function especially in patients with BCLC substage B2...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Satoshi Kobayashi, Taito Fukushima, Makoto Ueno, Satoshi Moriya, Makoto Chuma, Kazushi Numata, Kota Tsuruya, Shunji Hirose, Tatehiro Kagawa, Nobuhiro Hattori, Tsunamasa Watanabe, Kotaro Matsunaga, Michihiro Suzuki, Haruki Uojima, Hisashi Hidaka, Chika Kusano, Motoko Suzuki, Manabu Morimoto
פורמט: Artigo
שפה:Inglês
יצא לאור: BMC 2022-05-01
סדרה:BMC Cancer
נושאים:
Hepatocellular carcinoma
Intermediate stage
Substage
Lenvatinib
TACE
גישה מקוונת:https://doi.org/10.1186/s12885-022-09625-x
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים